Multi-interface licensing of protein import into a phage nucleus
- PMID: 39910297
- PMCID: PMC12165441
- DOI: 10.1038/s41586-024-08547-x
Multi-interface licensing of protein import into a phage nucleus
Abstract
Bacteriophages use diverse mechanisms to evade antiphage defence systems. ΦKZ-like jumbo phages assemble a proteinaceous, nucleus-like compartment that excludes antagonistic host nucleases and also internalizes DNA replication and transcription machinery1-4. The phage factors required for protein import and the mechanisms of selectivity remain unknown, however. Here we uncover an import system comprising proteins highly conserved across nucleus-forming phages, together with additional cargo-specific contributors. Using a genetic selection that forces the phage to decrease or abolish the import of specific proteins, we determine that the importation of five different phage nuclear-localized proteins requires distinct interfaces of the same factor, Imp1 (gp69). Imp1 localizes early to the nascent phage nucleus and forms discrete puncta in the mature phage nuclear periphery, probably in complex with direct interactor Imp6 (gp67), a conserved protein encoded in the same locus. The import of certain proteins, including a host topoisomerase, additionally requires Imp3 (gp59), a conserved factor necessary for proper Imp1 function. Three additional non-conserved phage proteins (Imp2 and Imp4/Imp5) are required for the import of two queried nuclear cargos (nuclear-localized protein 1 and host topoisomerase, respectively), perhaps acting as specific adaptors. We therefore propose a core import system that includes Imp1, Imp3 and Imp6, with multiple interfaces of Imp1 licensing transport through a protein lattice.
© 2025. The Author(s), under exclusive licence to Springer Nature Limited.
Conflict of interest statement
Competing interests: J.B.-D. is a scientific advisory board member of SNIPR Biome and Excision Biotherapeutics, a consultant to LeapFrog Bio and a scientific advisory board member and cofounder of Acrigen Biosciences and ePhective Therapeutics. S.S. is cofounder and equity holder in BillionToOne, Inc. and a scientific advisory board member for Junevity, Inc. The remaining authors declare no competing interests. The Bondy–Denomy laboratory received past research support from Felix Biotechnology.
Figures










References
-
- Malone LM et al. A jumbo phage that forms a nucleus-like structure evades CRISPR--Cas DNA targeting but is vulnerable to type III RNA-based immunity. Nature Microbiology 5, 48–55 (2020). - PubMed
Methods References
-
- Choi K-H & Schweizer HP mini-Tn7 insertion in bacteria with single attTn7 sites: example Pseudomonas aeruginosa. Nat. Protoc 1, 153–161 (2006). - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous